Global Biogeneric Drugs Market Research Report 2024(Status and Outlook)
Report Overview
Biogenerics drugs are the biological products manufactured after end of patent of innovator biopharmaceuticals. Biogenerics also known as biosimilars in Europe, follows-on-biologics in US and subsequent entry biological in japan. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. Biogenerics drugs provide effective treatment for number of serious and life-threatening illness because of their high specificity and activity. Biogeneric are more complex compared to small molecule drugs. Their quality and safety are highly dependent on the process of production (choice of cell type, development of the genetically modified cell for production, etc.), purification and formulation. The constitution of the biogeneric drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biogeneric drugs are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biogenerics can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biogeneric drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.
This report provides a deep insight into the global Biogeneric Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Biogeneric Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Biogeneric Drugs market in any manner.
Global Biogeneric Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sandoz International
Teva pharmaceutical industries
Mylan
3SBio
Shanghai Fosun Pharmaceutical
Tonghua Dongbao Pharmaceutical
Biocon
Reliance life sciences
Probiomed
Biosidus
AMEGA Biotech
Celltrion
LG life Science
Dong-A Pharmaceutical
Market Segmentation (by Type)
Insulins
Growth Hormones
Monoclonal Antibodies
Others
Market Segmentation (by Application)
Hospital
Clinics
Research Centers
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Biogeneric Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Biogenerics drugs are the biological products manufactured after end of patent of innovator biopharmaceuticals. Biogenerics also known as biosimilars in Europe, follows-on-biologics in US and subsequent entry biological in japan. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. Biogenerics drugs provide effective treatment for number of serious and life-threatening illness because of their high specificity and activity. Biogeneric are more complex compared to small molecule drugs. Their quality and safety are highly dependent on the process of production (choice of cell type, development of the genetically modified cell for production, etc.), purification and formulation. The constitution of the biogeneric drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biogeneric drugs are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biogenerics can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biogeneric drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.
This report provides a deep insight into the global Biogeneric Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Biogeneric Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Biogeneric Drugs market in any manner.
Global Biogeneric Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sandoz International
Teva pharmaceutical industries
Mylan
3SBio
Shanghai Fosun Pharmaceutical
Tonghua Dongbao Pharmaceutical
Biocon
Reliance life sciences
Probiomed
Biosidus
AMEGA Biotech
Celltrion
LG life Science
Dong-A Pharmaceutical
Market Segmentation (by Type)
Insulins
Growth Hormones
Monoclonal Antibodies
Others
Market Segmentation (by Application)
Hospital
Clinics
Research Centers
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Biogeneric Drugs Market
- Overview of the regional outlook of the Biogeneric Drugs Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Biogeneric Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Biogeneric Drugs
1.2 Key Market Segments
1.2.1 Biogeneric Drugs Segment by Type
1.2.2 Biogeneric Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 BIOGENERIC DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Biogeneric Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Biogeneric Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 BIOGENERIC DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Biogeneric Drugs Sales by Manufacturers (2019-2024)
3.2 Global Biogeneric Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Biogeneric Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Biogeneric Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Biogeneric Drugs Sales Sites, Area Served, Product Type
3.6 Biogeneric Drugs Market Competitive Situation and Trends
3.6.1 Biogeneric Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Biogeneric Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 BIOGENERIC DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Biogeneric Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF BIOGENERIC DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 BIOGENERIC DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Biogeneric Drugs Sales Market Share by Type (2019-2024)
6.3 Global Biogeneric Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Biogeneric Drugs Price by Type (2019-2024)
7 BIOGENERIC DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Biogeneric Drugs Market Sales by Application (2019-2024)
7.3 Global Biogeneric Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Biogeneric Drugs Sales Growth Rate by Application (2019-2024)
8 BIOGENERIC DRUGS MARKET SEGMENTATION BY REGION
8.1 Global Biogeneric Drugs Sales by Region
8.1.1 Global Biogeneric Drugs Sales by Region
8.1.2 Global Biogeneric Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Biogeneric Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Biogeneric Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Biogeneric Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Biogeneric Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Biogeneric Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Sandoz International
9.1.1 Sandoz International Biogeneric Drugs Basic Information
9.1.2 Sandoz International Biogeneric Drugs Product Overview
9.1.3 Sandoz International Biogeneric Drugs Product Market Performance
9.1.4 Sandoz International Business Overview
9.1.5 Sandoz International Biogeneric Drugs SWOT Analysis
9.1.6 Sandoz International Recent Developments
9.2 Teva pharmaceutical industries
9.2.1 Teva pharmaceutical industries Biogeneric Drugs Basic Information
9.2.2 Teva pharmaceutical industries Biogeneric Drugs Product Overview
9.2.3 Teva pharmaceutical industries Biogeneric Drugs Product Market Performance
9.2.4 Teva pharmaceutical industries Business Overview
9.2.5 Teva pharmaceutical industries Biogeneric Drugs SWOT Analysis
9.2.6 Teva pharmaceutical industries Recent Developments
9.3 Mylan
9.3.1 Mylan Biogeneric Drugs Basic Information
9.3.2 Mylan Biogeneric Drugs Product Overview
9.3.3 Mylan Biogeneric Drugs Product Market Performance
9.3.4 Mylan Biogeneric Drugs SWOT Analysis
9.3.5 Mylan Business Overview
9.3.6 Mylan Recent Developments
9.4 3SBio
9.4.1 3SBio Biogeneric Drugs Basic Information
9.4.2 3SBio Biogeneric Drugs Product Overview
9.4.3 3SBio Biogeneric Drugs Product Market Performance
9.4.4 3SBio Business Overview
9.4.5 3SBio Recent Developments
9.5 Shanghai Fosun Pharmaceutical
9.5.1 Shanghai Fosun Pharmaceutical Biogeneric Drugs Basic Information
9.5.2 Shanghai Fosun Pharmaceutical Biogeneric Drugs Product Overview
9.5.3 Shanghai Fosun Pharmaceutical Biogeneric Drugs Product Market Performance
9.5.4 Shanghai Fosun Pharmaceutical Business Overview
9.5.5 Shanghai Fosun Pharmaceutical Recent Developments
9.6 Tonghua Dongbao Pharmaceutical
9.6.1 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Basic Information
9.6.2 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Product Overview
9.6.3 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Product Market Performance
9.6.4 Tonghua Dongbao Pharmaceutical Business Overview
9.6.5 Tonghua Dongbao Pharmaceutical Recent Developments
9.7 Biocon
9.7.1 Biocon Biogeneric Drugs Basic Information
9.7.2 Biocon Biogeneric Drugs Product Overview
9.7.3 Biocon Biogeneric Drugs Product Market Performance
9.7.4 Biocon Business Overview
9.7.5 Biocon Recent Developments
9.8 Reliance life sciences
9.8.1 Reliance life sciences Biogeneric Drugs Basic Information
9.8.2 Reliance life sciences Biogeneric Drugs Product Overview
9.8.3 Reliance life sciences Biogeneric Drugs Product Market Performance
9.8.4 Reliance life sciences Business Overview
9.8.5 Reliance life sciences Recent Developments
9.9 Probiomed
9.9.1 Probiomed Biogeneric Drugs Basic Information
9.9.2 Probiomed Biogeneric Drugs Product Overview
9.9.3 Probiomed Biogeneric Drugs Product Market Performance
9.9.4 Probiomed Business Overview
9.9.5 Probiomed Recent Developments
9.10 Biosidus
9.10.1 Biosidus Biogeneric Drugs Basic Information
9.10.2 Biosidus Biogeneric Drugs Product Overview
9.10.3 Biosidus Biogeneric Drugs Product Market Performance
9.10.4 Biosidus Business Overview
9.10.5 Biosidus Recent Developments
9.11 AMEGA Biotech
9.11.1 AMEGA Biotech Biogeneric Drugs Basic Information
9.11.2 AMEGA Biotech Biogeneric Drugs Product Overview
9.11.3 AMEGA Biotech Biogeneric Drugs Product Market Performance
9.11.4 AMEGA Biotech Business Overview
9.11.5 AMEGA Biotech Recent Developments
9.12 Celltrion
9.12.1 Celltrion Biogeneric Drugs Basic Information
9.12.2 Celltrion Biogeneric Drugs Product Overview
9.12.3 Celltrion Biogeneric Drugs Product Market Performance
9.12.4 Celltrion Business Overview
9.12.5 Celltrion Recent Developments
9.13 LG life Science
9.13.1 LG life Science Biogeneric Drugs Basic Information
9.13.2 LG life Science Biogeneric Drugs Product Overview
9.13.3 LG life Science Biogeneric Drugs Product Market Performance
9.13.4 LG life Science Business Overview
9.13.5 LG life Science Recent Developments
9.14 Dong-A Pharmaceutical
9.14.1 Dong-A Pharmaceutical Biogeneric Drugs Basic Information
9.14.2 Dong-A Pharmaceutical Biogeneric Drugs Product Overview
9.14.3 Dong-A Pharmaceutical Biogeneric Drugs Product Market Performance
9.14.4 Dong-A Pharmaceutical Business Overview
9.14.5 Dong-A Pharmaceutical Recent Developments
10 BIOGENERIC DRUGS MARKET FORECAST BY REGION
10.1 Global Biogeneric Drugs Market Size Forecast
10.2 Global Biogeneric Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Biogeneric Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Biogeneric Drugs Market Size Forecast by Region
10.2.4 South America Biogeneric Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Biogeneric Drugs by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Biogeneric Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Biogeneric Drugs by Type (2025-2030)
11.1.2 Global Biogeneric Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Biogeneric Drugs by Type (2025-2030)
11.2 Global Biogeneric Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Biogeneric Drugs Sales (Kilotons) Forecast by Application
11.2.2 Global Biogeneric Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Biogeneric Drugs
1.2 Key Market Segments
1.2.1 Biogeneric Drugs Segment by Type
1.2.2 Biogeneric Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 BIOGENERIC DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Biogeneric Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Biogeneric Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 BIOGENERIC DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Biogeneric Drugs Sales by Manufacturers (2019-2024)
3.2 Global Biogeneric Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Biogeneric Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Biogeneric Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Biogeneric Drugs Sales Sites, Area Served, Product Type
3.6 Biogeneric Drugs Market Competitive Situation and Trends
3.6.1 Biogeneric Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Biogeneric Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 BIOGENERIC DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Biogeneric Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF BIOGENERIC DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 BIOGENERIC DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Biogeneric Drugs Sales Market Share by Type (2019-2024)
6.3 Global Biogeneric Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Biogeneric Drugs Price by Type (2019-2024)
7 BIOGENERIC DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Biogeneric Drugs Market Sales by Application (2019-2024)
7.3 Global Biogeneric Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Biogeneric Drugs Sales Growth Rate by Application (2019-2024)
8 BIOGENERIC DRUGS MARKET SEGMENTATION BY REGION
8.1 Global Biogeneric Drugs Sales by Region
8.1.1 Global Biogeneric Drugs Sales by Region
8.1.2 Global Biogeneric Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Biogeneric Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Biogeneric Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Biogeneric Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Biogeneric Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Biogeneric Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Sandoz International
9.1.1 Sandoz International Biogeneric Drugs Basic Information
9.1.2 Sandoz International Biogeneric Drugs Product Overview
9.1.3 Sandoz International Biogeneric Drugs Product Market Performance
9.1.4 Sandoz International Business Overview
9.1.5 Sandoz International Biogeneric Drugs SWOT Analysis
9.1.6 Sandoz International Recent Developments
9.2 Teva pharmaceutical industries
9.2.1 Teva pharmaceutical industries Biogeneric Drugs Basic Information
9.2.2 Teva pharmaceutical industries Biogeneric Drugs Product Overview
9.2.3 Teva pharmaceutical industries Biogeneric Drugs Product Market Performance
9.2.4 Teva pharmaceutical industries Business Overview
9.2.5 Teva pharmaceutical industries Biogeneric Drugs SWOT Analysis
9.2.6 Teva pharmaceutical industries Recent Developments
9.3 Mylan
9.3.1 Mylan Biogeneric Drugs Basic Information
9.3.2 Mylan Biogeneric Drugs Product Overview
9.3.3 Mylan Biogeneric Drugs Product Market Performance
9.3.4 Mylan Biogeneric Drugs SWOT Analysis
9.3.5 Mylan Business Overview
9.3.6 Mylan Recent Developments
9.4 3SBio
9.4.1 3SBio Biogeneric Drugs Basic Information
9.4.2 3SBio Biogeneric Drugs Product Overview
9.4.3 3SBio Biogeneric Drugs Product Market Performance
9.4.4 3SBio Business Overview
9.4.5 3SBio Recent Developments
9.5 Shanghai Fosun Pharmaceutical
9.5.1 Shanghai Fosun Pharmaceutical Biogeneric Drugs Basic Information
9.5.2 Shanghai Fosun Pharmaceutical Biogeneric Drugs Product Overview
9.5.3 Shanghai Fosun Pharmaceutical Biogeneric Drugs Product Market Performance
9.5.4 Shanghai Fosun Pharmaceutical Business Overview
9.5.5 Shanghai Fosun Pharmaceutical Recent Developments
9.6 Tonghua Dongbao Pharmaceutical
9.6.1 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Basic Information
9.6.2 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Product Overview
9.6.3 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Product Market Performance
9.6.4 Tonghua Dongbao Pharmaceutical Business Overview
9.6.5 Tonghua Dongbao Pharmaceutical Recent Developments
9.7 Biocon
9.7.1 Biocon Biogeneric Drugs Basic Information
9.7.2 Biocon Biogeneric Drugs Product Overview
9.7.3 Biocon Biogeneric Drugs Product Market Performance
9.7.4 Biocon Business Overview
9.7.5 Biocon Recent Developments
9.8 Reliance life sciences
9.8.1 Reliance life sciences Biogeneric Drugs Basic Information
9.8.2 Reliance life sciences Biogeneric Drugs Product Overview
9.8.3 Reliance life sciences Biogeneric Drugs Product Market Performance
9.8.4 Reliance life sciences Business Overview
9.8.5 Reliance life sciences Recent Developments
9.9 Probiomed
9.9.1 Probiomed Biogeneric Drugs Basic Information
9.9.2 Probiomed Biogeneric Drugs Product Overview
9.9.3 Probiomed Biogeneric Drugs Product Market Performance
9.9.4 Probiomed Business Overview
9.9.5 Probiomed Recent Developments
9.10 Biosidus
9.10.1 Biosidus Biogeneric Drugs Basic Information
9.10.2 Biosidus Biogeneric Drugs Product Overview
9.10.3 Biosidus Biogeneric Drugs Product Market Performance
9.10.4 Biosidus Business Overview
9.10.5 Biosidus Recent Developments
9.11 AMEGA Biotech
9.11.1 AMEGA Biotech Biogeneric Drugs Basic Information
9.11.2 AMEGA Biotech Biogeneric Drugs Product Overview
9.11.3 AMEGA Biotech Biogeneric Drugs Product Market Performance
9.11.4 AMEGA Biotech Business Overview
9.11.5 AMEGA Biotech Recent Developments
9.12 Celltrion
9.12.1 Celltrion Biogeneric Drugs Basic Information
9.12.2 Celltrion Biogeneric Drugs Product Overview
9.12.3 Celltrion Biogeneric Drugs Product Market Performance
9.12.4 Celltrion Business Overview
9.12.5 Celltrion Recent Developments
9.13 LG life Science
9.13.1 LG life Science Biogeneric Drugs Basic Information
9.13.2 LG life Science Biogeneric Drugs Product Overview
9.13.3 LG life Science Biogeneric Drugs Product Market Performance
9.13.4 LG life Science Business Overview
9.13.5 LG life Science Recent Developments
9.14 Dong-A Pharmaceutical
9.14.1 Dong-A Pharmaceutical Biogeneric Drugs Basic Information
9.14.2 Dong-A Pharmaceutical Biogeneric Drugs Product Overview
9.14.3 Dong-A Pharmaceutical Biogeneric Drugs Product Market Performance
9.14.4 Dong-A Pharmaceutical Business Overview
9.14.5 Dong-A Pharmaceutical Recent Developments
10 BIOGENERIC DRUGS MARKET FORECAST BY REGION
10.1 Global Biogeneric Drugs Market Size Forecast
10.2 Global Biogeneric Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Biogeneric Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Biogeneric Drugs Market Size Forecast by Region
10.2.4 South America Biogeneric Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Biogeneric Drugs by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Biogeneric Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Biogeneric Drugs by Type (2025-2030)
11.1.2 Global Biogeneric Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Biogeneric Drugs by Type (2025-2030)
11.2 Global Biogeneric Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Biogeneric Drugs Sales (Kilotons) Forecast by Application
11.2.2 Global Biogeneric Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Biogeneric Drugs Market Size Comparison by Region (M USD)
Table 5. Global Biogeneric Drugs Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Biogeneric Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Biogeneric Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Biogeneric Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biogeneric Drugs as of 2022)
Table 10. Global Market Biogeneric Drugs Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Biogeneric Drugs Sales Sites and Area Served
Table 12. Manufacturers Biogeneric Drugs Product Type
Table 13. Global Biogeneric Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Biogeneric Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Biogeneric Drugs Market Challenges
Table 22. Global Biogeneric Drugs Sales by Type (Kilotons)
Table 23. Global Biogeneric Drugs Market Size by Type (M USD)
Table 24. Global Biogeneric Drugs Sales (Kilotons) by Type (2019-2024)
Table 25. Global Biogeneric Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Biogeneric Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Biogeneric Drugs Market Size Share by Type (2019-2024)
Table 28. Global Biogeneric Drugs Price (USD/Ton) by Type (2019-2024)
Table 29. Global Biogeneric Drugs Sales (Kilotons) by Application
Table 30. Global Biogeneric Drugs Market Size by Application
Table 31. Global Biogeneric Drugs Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Biogeneric Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Biogeneric Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Biogeneric Drugs Market Share by Application (2019-2024)
Table 35. Global Biogeneric Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Biogeneric Drugs Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Biogeneric Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Biogeneric Drugs Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Biogeneric Drugs Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Biogeneric Drugs Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Biogeneric Drugs Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Biogeneric Drugs Sales by Region (2019-2024) & (Kilotons)
Table 43. Sandoz International Biogeneric Drugs Basic Information
Table 44. Sandoz International Biogeneric Drugs Product Overview
Table 45. Sandoz International Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Sandoz International Business Overview
Table 47. Sandoz International Biogeneric Drugs SWOT Analysis
Table 48. Sandoz International Recent Developments
Table 49. Teva pharmaceutical industries Biogeneric Drugs Basic Information
Table 50. Teva pharmaceutical industries Biogeneric Drugs Product Overview
Table 51. Teva pharmaceutical industries Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Teva pharmaceutical industries Business Overview
Table 53. Teva pharmaceutical industries Biogeneric Drugs SWOT Analysis
Table 54. Teva pharmaceutical industries Recent Developments
Table 55. Mylan Biogeneric Drugs Basic Information
Table 56. Mylan Biogeneric Drugs Product Overview
Table 57. Mylan Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Mylan Biogeneric Drugs SWOT Analysis
Table 59. Mylan Business Overview
Table 60. Mylan Recent Developments
Table 61. 3SBio Biogeneric Drugs Basic Information
Table 62. 3SBio Biogeneric Drugs Product Overview
Table 63. 3SBio Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. 3SBio Business Overview
Table 65. 3SBio Recent Developments
Table 66. Shanghai Fosun Pharmaceutical Biogeneric Drugs Basic Information
Table 67. Shanghai Fosun Pharmaceutical Biogeneric Drugs Product Overview
Table 68. Shanghai Fosun Pharmaceutical Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Shanghai Fosun Pharmaceutical Business Overview
Table 70. Shanghai Fosun Pharmaceutical Recent Developments
Table 71. Tonghua Dongbao Pharmaceutical Biogeneric Drugs Basic Information
Table 72. Tonghua Dongbao Pharmaceutical Biogeneric Drugs Product Overview
Table 73. Tonghua Dongbao Pharmaceutical Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Tonghua Dongbao Pharmaceutical Business Overview
Table 75. Tonghua Dongbao Pharmaceutical Recent Developments
Table 76. Biocon Biogeneric Drugs Basic Information
Table 77. Biocon Biogeneric Drugs Product Overview
Table 78. Biocon Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Biocon Business Overview
Table 80. Biocon Recent Developments
Table 81. Reliance life sciences Biogeneric Drugs Basic Information
Table 82. Reliance life sciences Biogeneric Drugs Product Overview
Table 83. Reliance life sciences Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Reliance life sciences Business Overview
Table 85. Reliance life sciences Recent Developments
Table 86. Probiomed Biogeneric Drugs Basic Information
Table 87. Probiomed Biogeneric Drugs Product Overview
Table 88. Probiomed Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Probiomed Business Overview
Table 90. Probiomed Recent Developments
Table 91. Biosidus Biogeneric Drugs Basic Information
Table 92. Biosidus Biogeneric Drugs Product Overview
Table 93. Biosidus Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Biosidus Business Overview
Table 95. Biosidus Recent Developments
Table 96. AMEGA Biotech Biogeneric Drugs Basic Information
Table 97. AMEGA Biotech Biogeneric Drugs Product Overview
Table 98. AMEGA Biotech Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. AMEGA Biotech Business Overview
Table 100. AMEGA Biotech Recent Developments
Table 101. Celltrion Biogeneric Drugs Basic Information
Table 102. Celltrion Biogeneric Drugs Product Overview
Table 103. Celltrion Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Celltrion Business Overview
Table 105. Celltrion Recent Developments
Table 106. LG life Science Biogeneric Drugs Basic Information
Table 107. LG life Science Biogeneric Drugs Product Overview
Table 108. LG life Science Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. LG life Science Business Overview
Table 110. LG life Science Recent Developments
Table 111. Dong-A Pharmaceutical Biogeneric Drugs Basic Information
Table 112. Dong-A Pharmaceutical Biogeneric Drugs Product Overview
Table 113. Dong-A Pharmaceutical Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Dong-A Pharmaceutical Business Overview
Table 115. Dong-A Pharmaceutical Recent Developments
Table 116. Global Biogeneric Drugs Sales Forecast by Region (2025-2030) & (Kilotons)
Table 117. Global Biogeneric Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 118. North America Biogeneric Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 119. North America Biogeneric Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 120. Europe Biogeneric Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 121. Europe Biogeneric Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 122. Asia Pacific Biogeneric Drugs Sales Forecast by Region (2025-2030) & (Kilotons)
Table 123. Asia Pacific Biogeneric Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 124. South America Biogeneric Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 125. South America Biogeneric Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 126. Middle East and Africa Biogeneric Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 127. Middle East and Africa Biogeneric Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 128. Global Biogeneric Drugs Sales Forecast by Type (2025-2030) & (Kilotons)
Table 129. Global Biogeneric Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 130. Global Biogeneric Drugs Price Forecast by Type (2025-2030) & (USD/Ton)
Table 131. Global Biogeneric Drugs Sales (Kilotons) Forecast by Application (2025-2030)
Table 132. Global Biogeneric Drugs Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Biogeneric Drugs Market Size Comparison by Region (M USD)
Table 5. Global Biogeneric Drugs Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Biogeneric Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Biogeneric Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Biogeneric Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biogeneric Drugs as of 2022)
Table 10. Global Market Biogeneric Drugs Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Biogeneric Drugs Sales Sites and Area Served
Table 12. Manufacturers Biogeneric Drugs Product Type
Table 13. Global Biogeneric Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Biogeneric Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Biogeneric Drugs Market Challenges
Table 22. Global Biogeneric Drugs Sales by Type (Kilotons)
Table 23. Global Biogeneric Drugs Market Size by Type (M USD)
Table 24. Global Biogeneric Drugs Sales (Kilotons) by Type (2019-2024)
Table 25. Global Biogeneric Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Biogeneric Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Biogeneric Drugs Market Size Share by Type (2019-2024)
Table 28. Global Biogeneric Drugs Price (USD/Ton) by Type (2019-2024)
Table 29. Global Biogeneric Drugs Sales (Kilotons) by Application
Table 30. Global Biogeneric Drugs Market Size by Application
Table 31. Global Biogeneric Drugs Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Biogeneric Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Biogeneric Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Biogeneric Drugs Market Share by Application (2019-2024)
Table 35. Global Biogeneric Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Biogeneric Drugs Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Biogeneric Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Biogeneric Drugs Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Biogeneric Drugs Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Biogeneric Drugs Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Biogeneric Drugs Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Biogeneric Drugs Sales by Region (2019-2024) & (Kilotons)
Table 43. Sandoz International Biogeneric Drugs Basic Information
Table 44. Sandoz International Biogeneric Drugs Product Overview
Table 45. Sandoz International Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Sandoz International Business Overview
Table 47. Sandoz International Biogeneric Drugs SWOT Analysis
Table 48. Sandoz International Recent Developments
Table 49. Teva pharmaceutical industries Biogeneric Drugs Basic Information
Table 50. Teva pharmaceutical industries Biogeneric Drugs Product Overview
Table 51. Teva pharmaceutical industries Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Teva pharmaceutical industries Business Overview
Table 53. Teva pharmaceutical industries Biogeneric Drugs SWOT Analysis
Table 54. Teva pharmaceutical industries Recent Developments
Table 55. Mylan Biogeneric Drugs Basic Information
Table 56. Mylan Biogeneric Drugs Product Overview
Table 57. Mylan Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Mylan Biogeneric Drugs SWOT Analysis
Table 59. Mylan Business Overview
Table 60. Mylan Recent Developments
Table 61. 3SBio Biogeneric Drugs Basic Information
Table 62. 3SBio Biogeneric Drugs Product Overview
Table 63. 3SBio Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. 3SBio Business Overview
Table 65. 3SBio Recent Developments
Table 66. Shanghai Fosun Pharmaceutical Biogeneric Drugs Basic Information
Table 67. Shanghai Fosun Pharmaceutical Biogeneric Drugs Product Overview
Table 68. Shanghai Fosun Pharmaceutical Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Shanghai Fosun Pharmaceutical Business Overview
Table 70. Shanghai Fosun Pharmaceutical Recent Developments
Table 71. Tonghua Dongbao Pharmaceutical Biogeneric Drugs Basic Information
Table 72. Tonghua Dongbao Pharmaceutical Biogeneric Drugs Product Overview
Table 73. Tonghua Dongbao Pharmaceutical Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Tonghua Dongbao Pharmaceutical Business Overview
Table 75. Tonghua Dongbao Pharmaceutical Recent Developments
Table 76. Biocon Biogeneric Drugs Basic Information
Table 77. Biocon Biogeneric Drugs Product Overview
Table 78. Biocon Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Biocon Business Overview
Table 80. Biocon Recent Developments
Table 81. Reliance life sciences Biogeneric Drugs Basic Information
Table 82. Reliance life sciences Biogeneric Drugs Product Overview
Table 83. Reliance life sciences Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Reliance life sciences Business Overview
Table 85. Reliance life sciences Recent Developments
Table 86. Probiomed Biogeneric Drugs Basic Information
Table 87. Probiomed Biogeneric Drugs Product Overview
Table 88. Probiomed Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Probiomed Business Overview
Table 90. Probiomed Recent Developments
Table 91. Biosidus Biogeneric Drugs Basic Information
Table 92. Biosidus Biogeneric Drugs Product Overview
Table 93. Biosidus Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Biosidus Business Overview
Table 95. Biosidus Recent Developments
Table 96. AMEGA Biotech Biogeneric Drugs Basic Information
Table 97. AMEGA Biotech Biogeneric Drugs Product Overview
Table 98. AMEGA Biotech Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. AMEGA Biotech Business Overview
Table 100. AMEGA Biotech Recent Developments
Table 101. Celltrion Biogeneric Drugs Basic Information
Table 102. Celltrion Biogeneric Drugs Product Overview
Table 103. Celltrion Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Celltrion Business Overview
Table 105. Celltrion Recent Developments
Table 106. LG life Science Biogeneric Drugs Basic Information
Table 107. LG life Science Biogeneric Drugs Product Overview
Table 108. LG life Science Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. LG life Science Business Overview
Table 110. LG life Science Recent Developments
Table 111. Dong-A Pharmaceutical Biogeneric Drugs Basic Information
Table 112. Dong-A Pharmaceutical Biogeneric Drugs Product Overview
Table 113. Dong-A Pharmaceutical Biogeneric Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Dong-A Pharmaceutical Business Overview
Table 115. Dong-A Pharmaceutical Recent Developments
Table 116. Global Biogeneric Drugs Sales Forecast by Region (2025-2030) & (Kilotons)
Table 117. Global Biogeneric Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 118. North America Biogeneric Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 119. North America Biogeneric Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 120. Europe Biogeneric Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 121. Europe Biogeneric Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 122. Asia Pacific Biogeneric Drugs Sales Forecast by Region (2025-2030) & (Kilotons)
Table 123. Asia Pacific Biogeneric Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 124. South America Biogeneric Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 125. South America Biogeneric Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 126. Middle East and Africa Biogeneric Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 127. Middle East and Africa Biogeneric Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 128. Global Biogeneric Drugs Sales Forecast by Type (2025-2030) & (Kilotons)
Table 129. Global Biogeneric Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 130. Global Biogeneric Drugs Price Forecast by Type (2025-2030) & (USD/Ton)
Table 131. Global Biogeneric Drugs Sales (Kilotons) Forecast by Application (2025-2030)
Table 132. Global Biogeneric Drugs Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Biogeneric Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Biogeneric Drugs Market Size (M USD), 2019-2030
Figure 5. Global Biogeneric Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Biogeneric Drugs Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Biogeneric Drugs Market Size by Country (M USD)
Figure 11. Biogeneric Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Biogeneric Drugs Revenue Share by Manufacturers in 2023
Figure 13. Biogeneric Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Biogeneric Drugs Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Biogeneric Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Biogeneric Drugs Market Share by Type
Figure 18. Sales Market Share of Biogeneric Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Biogeneric Drugs by Type in 2023
Figure 20. Market Size Share of Biogeneric Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Biogeneric Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Biogeneric Drugs Market Share by Application
Figure 24. Global Biogeneric Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Biogeneric Drugs Sales Market Share by Application in 2023
Figure 26. Global Biogeneric Drugs Market Share by Application (2019-2024)
Figure 27. Global Biogeneric Drugs Market Share by Application in 2023
Figure 28. Global Biogeneric Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Biogeneric Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Biogeneric Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Biogeneric Drugs Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Biogeneric Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Biogeneric Drugs Sales Market Share by Country in 2023
Figure 37. Germany Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Biogeneric Drugs Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Biogeneric Drugs Sales Market Share by Region in 2023
Figure 44. China Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Biogeneric Drugs Sales and Growth Rate (Kilotons)
Figure 50. South America Biogeneric Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Biogeneric Drugs Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Biogeneric Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Biogeneric Drugs Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Biogeneric Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Biogeneric Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Biogeneric Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Biogeneric Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Biogeneric Drugs Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Biogeneric Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Biogeneric Drugs Market Size (M USD), 2019-2030
Figure 5. Global Biogeneric Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Biogeneric Drugs Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Biogeneric Drugs Market Size by Country (M USD)
Figure 11. Biogeneric Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Biogeneric Drugs Revenue Share by Manufacturers in 2023
Figure 13. Biogeneric Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Biogeneric Drugs Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Biogeneric Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Biogeneric Drugs Market Share by Type
Figure 18. Sales Market Share of Biogeneric Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Biogeneric Drugs by Type in 2023
Figure 20. Market Size Share of Biogeneric Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Biogeneric Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Biogeneric Drugs Market Share by Application
Figure 24. Global Biogeneric Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Biogeneric Drugs Sales Market Share by Application in 2023
Figure 26. Global Biogeneric Drugs Market Share by Application (2019-2024)
Figure 27. Global Biogeneric Drugs Market Share by Application in 2023
Figure 28. Global Biogeneric Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Biogeneric Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Biogeneric Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Biogeneric Drugs Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Biogeneric Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Biogeneric Drugs Sales Market Share by Country in 2023
Figure 37. Germany Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Biogeneric Drugs Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Biogeneric Drugs Sales Market Share by Region in 2023
Figure 44. China Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Biogeneric Drugs Sales and Growth Rate (Kilotons)
Figure 50. South America Biogeneric Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Biogeneric Drugs Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Biogeneric Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Biogeneric Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Biogeneric Drugs Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Biogeneric Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Biogeneric Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Biogeneric Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Biogeneric Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Biogeneric Drugs Market Share Forecast by Application (2025-2030)
